Skip to main content
Premium Trial:

Request an Annual Quote

Sengenics to Sell Sequenom's MaterniT21 Test in Malaysia, Singapore

NEW YORK (GenomeWeb News) – Sengenics today said that it has entered into an exclusive agreement with the Sequenom Center for Molecular Medicine to launch and promote Sequenom's MaterniT21 Plus prenatal testing service in Malaysia and Singapore.

Sengenics will offer the test, which detects Trisomy 13, 18, and 21, to its partner Ob/Gyn clinicians and hospitals in the two countries. Sengenics is based in Kuala Lumpur and offers genomic-based diagnostic services. It added that it has contracts with eight of the top 10 private hospital chains in the region.

Sequenom on Friday said that it has reached a 90,000 annualized test volume run rate for MaterniT21, approximately one year after the test was launched in the US.